Overactive bladder (OAB) is the name of group of urinary symptoms. It is not a disease. The most common symptom is a sudden, uncontrolled need to urge to urinate. Some people will leak urine when they feel such urge. Another symptom is the need to pass urine many times during the day and night. According to the estimates released by the Urology Care Foundation, as many as 30% of men and 40% women in the US live with OAB symptoms.

Market Drivers

Innovative therapy treatments bolster the growth of overactive bladder (OAB) treatment market

OAB is highly prevalent and has an impact on patient quality of life. The current oral medications of OAB include antimuscarinics and beta-3 adrenoceptor agonists. In patients refractory to such OAB medications, intravesical Botox injections has been documented as third line of treatment according to the American Urological Association (AUA) and European Association of Urology guidelines. Antimuscarinic drugs have gained significant prominence in the treatment of overactive bladder (OAB) since two decades. In February 2021, AbbVie Inc. announced that the US Food and Drug Administration (USFDA) has approved BOTOX® for the treatment of detrusor (bladder muscle) over activity associated with a neurological condition in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. Currently, BOTOX® is FDA-approved for 12 therapeutic indications, involving Chronic Migraine, overactive bladder, leakage of urine (incontinence) associated by overactive bladder caused due to neurological conditions in adults, cervical dystonia, spasticity, severe underarm sweating (axillary hyperhidrosis), and among others.

Geriatric population suffering from urinary disorders

According to the statistics released by the Center for Disease Control and Prevention (CDC), of non-institutionalized persons aged 65 years and over 50.9% reported a urinary leakage and/or accidental bowel leakage of mucus, liquid stool, or solid stool. Among them 43.8% reported a urinary leakage and 17.3% reported accidental bowel leakage. Additionally, the majority of them reported urinary but not accidental bowel leakage while 10.6% of non-institutional persons reported both urinary and bowel leakage. Incontinence presents a significant financial burden to the individual and to the society. According to the statistics released by the Agency for Healthcare Research and Quality (AHRQ), total direct healthcare cost for women with OAB in 2000 was estimated at US$ 6.9 Bn of which US$ 1.1 Bn was for pharmacological treatment and US$ 550 Mn for surgical treatment. In the US the cost of bladder incontinency among adults in 2000 was estimated at US$ 19.5 Bn, with US$ 14.2 Bn incurred by community residents and US$ 5.3 Bn incurred by institutional residents.

Surge in number of regulatory approvals for treatment of overactive bladder (OAB)

In November 2019, FDA approved the Axonics Sacral Neuromodulation (SNM) System that intends to treat urinary retention and the symptoms associated with overactive bladder (OAB). It is integrated by implanted stimulator that delivers electrical pulses through a lead wire to electrodes located near the sacral nerve. Moreover, in August 2020, Medtronic plc, announced receiving approval from the USFDA for its new product namely, InterStim™ SureScan™ MRI leads. InterStim™ SureScan™ MRI leads-the markets smallest rechargeable devices deliver sacral neuromodulation (SCM) therapy-is used for treatment of overactive bladder (OAB), fecal incontinency (FI), and non-obstructive urinary retention.

Segmental Outlook

Overactive bladder (OAB) treatment market is segmented based on pharmacotherapy and disease type. Pharmacotherapy is segmented as anticholinergics, solifenacin, oxybutynin, darifenacin, fesoterodine, tolterodine, trospium, and others. Based on disease type, the market is segmented as idiopathic bladder over activity and neurogenic bladder over activity.

Based on pharmacotherapy, anticholinergics will record a remarkable market share in the forecast period. Anticholinergics (ACs) are useful drugs for treatment of OAB. They are the first-line pharmacotherapy for overactive bladder syndrome by the clinicians. Anticholinergics are widely used class of medications for treatment of overactive bladder (OAB). These drugs have wide pharmacological actions such as inhibition of involuntary bladder contractions. The drugs approved by the FDA for treatment of OAB involve oxybutynin, tolterodine, fesoterodine or solifenacin. Additionally, FDA approved Myrbetriq (mirabegron), a medication that improves the bladder’s ability to store urine by relaxing the bladder muscle during filling.

Further, by disease type, idiopathic overactive bladder treatment segment is expected to mark significant revenue in the overactive bladder treatment market. The key factors responsible for the growth of this segment involves surge in prevalence of chronic kidney diseases (CKD) and rise in elderly population suffering from the disease. Also, due to bladder muscle weakness post-pregnancy and menopause, women are more vulnerable to suffer from this condition. In 2017, according to the National Association for Incontinence, urinary incontinence affects about 200 million people globally. This is anticipated to encourage prominent players to invest in such segment. Apart from that, increasing competition among the key players may lead to decrease the overall cost of treatment in the forecast period.

North America dominates the overactive bladder (OAB) treatment market

North America is dominating the overactive bladder (OAB) treatment market and will continue to dominate the forecast period. This is well supported due to the well-established healthcare industry coupled with infrastructure. With favorable reimbursement policies related to OAB, the growing incidences of disease with rising age and presence of prominent players fuels the growth during the forecast period. According to the USFDA, overactive bladder associated symptoms affect more than 33 million Americans. Major population doesn’t seek treatment possibly because of embarrassment and non-awareness regarding treatment options.

In the US, 30% of men and 40% of women live with overactive bladder symptoms. On the other hand, Asia Pacific is anticipated to record remarkable CAGR in the coming years contributing to the fullest for the growth of overactive bladder (OAB) treatment market. Rising awareness among the growing patient pool about chronic kidney diseases (CKD), overactive urinary bladder, and surge in healthcare expenditure are the factors responsible for stimulating the growth of APAC market for overactive bladder (OAB) treatment market. Europe is the second largest market revenue contributor for the overactive bladder (OAB) treatment market. Expansion of research and development units and pathology labs and favorable government policies coupled with development of healthcare infrastructure in European markets for overactive bladder (OAB) treatment market.

Competitive Landscape

Key companies profiled in this report involve Astellas Pharma, Inc., Pfizer, Inc., Teva Pharmaceutical Industries Limited, Allergan, Plc, Medtronic plc, Mylan N.V., Endo International plc, Hisamitsu Pharmaceutical Co., Inc., Sanofi, Aurobindo Pharma Limited, Apotex, Inc., and Cogentix Medical, Inc., and among others.

Market Segmentation

Market By Pharmacotherapy

Anticholinergics
Solifenacin
Oxybutynin
Darifenacin
Fesoterodine
Tolterodine
Trospium
Others

Market By Disease Type

Idiopathic Bladder Overactivity
Neurogenic Bladder Overactivity

Market By Geography

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa